A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients

A. Vigano, N. Principi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The efficacy and safety of isepamicin 7.5 mg/kg of body weight twice daily or amikacin at the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial. In total, 306 patients were enrolled and received at least one dose of randomised treatment (204 isepamicin, 102 amikacin: intent-to-treat population); 181 patients satisfied all criteria for evaluability (120 isepamicin, 61 amikacin: efficacy population). Clinical cure or improvement rates in the isepamicin and amikacin groups were: intent-to-treat population, 188/204 (92%) and 94/102 (92%), respectively; efficacy population, 117/120 (98%) and 58/61 (95%), respectively. The bacteriological elimination rate (efficacy population) in the isepamicin and amikacin treatment groups was 75/76 (99%) vs 35/38 (92%). Nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or ≥44.2 μmol/L from baseline, occurred in 4/187 (2%) and 1/91 (1%) children treated with isepamicin and amikacin, respectively. Definite ototoxicity at the ≥20 dB threshold occurred in 3 (1 isepamicin and 2 amikacin) out of 56 children evaluated with at least two audiograms. Thus isepamicin was as effective and as well tolerated as amikacin in the treatment of various infections in paediatric patients.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
JournalJournal of Chemotherapy
Volume7
Issue numberSUPPL. 2
Publication statusPublished - 1995

Fingerprint

Amikacin
Bacterial Infections
Pediatrics
Population
Therapeutics
isepamicin
Infection
Creatinine
Body Weight
Safety
Serum

Keywords

  • Amikacin
  • Aminoglycoside
  • Isepamicin
  • Paediatrics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. / Vigano, A.; Principi, N.

In: Journal of Chemotherapy, Vol. 7, No. SUPPL. 2, 1995, p. 95-101.

Research output: Contribution to journalArticle

@article{aef4dcc8c847450c8ed223579f6dea71,
title = "A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients",
abstract = "The efficacy and safety of isepamicin 7.5 mg/kg of body weight twice daily or amikacin at the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial. In total, 306 patients were enrolled and received at least one dose of randomised treatment (204 isepamicin, 102 amikacin: intent-to-treat population); 181 patients satisfied all criteria for evaluability (120 isepamicin, 61 amikacin: efficacy population). Clinical cure or improvement rates in the isepamicin and amikacin groups were: intent-to-treat population, 188/204 (92{\%}) and 94/102 (92{\%}), respectively; efficacy population, 117/120 (98{\%}) and 58/61 (95{\%}), respectively. The bacteriological elimination rate (efficacy population) in the isepamicin and amikacin treatment groups was 75/76 (99{\%}) vs 35/38 (92{\%}). Nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or ≥44.2 μmol/L from baseline, occurred in 4/187 (2{\%}) and 1/91 (1{\%}) children treated with isepamicin and amikacin, respectively. Definite ototoxicity at the ≥20 dB threshold occurred in 3 (1 isepamicin and 2 amikacin) out of 56 children evaluated with at least two audiograms. Thus isepamicin was as effective and as well tolerated as amikacin in the treatment of various infections in paediatric patients.",
keywords = "Amikacin, Aminoglycoside, Isepamicin, Paediatrics",
author = "A. Vigano and N. Principi",
year = "1995",
language = "English",
volume = "7",
pages = "95--101",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "SUPPL. 2",

}

TY - JOUR

T1 - A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients

AU - Vigano, A.

AU - Principi, N.

PY - 1995

Y1 - 1995

N2 - The efficacy and safety of isepamicin 7.5 mg/kg of body weight twice daily or amikacin at the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial. In total, 306 patients were enrolled and received at least one dose of randomised treatment (204 isepamicin, 102 amikacin: intent-to-treat population); 181 patients satisfied all criteria for evaluability (120 isepamicin, 61 amikacin: efficacy population). Clinical cure or improvement rates in the isepamicin and amikacin groups were: intent-to-treat population, 188/204 (92%) and 94/102 (92%), respectively; efficacy population, 117/120 (98%) and 58/61 (95%), respectively. The bacteriological elimination rate (efficacy population) in the isepamicin and amikacin treatment groups was 75/76 (99%) vs 35/38 (92%). Nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or ≥44.2 μmol/L from baseline, occurred in 4/187 (2%) and 1/91 (1%) children treated with isepamicin and amikacin, respectively. Definite ototoxicity at the ≥20 dB threshold occurred in 3 (1 isepamicin and 2 amikacin) out of 56 children evaluated with at least two audiograms. Thus isepamicin was as effective and as well tolerated as amikacin in the treatment of various infections in paediatric patients.

AB - The efficacy and safety of isepamicin 7.5 mg/kg of body weight twice daily or amikacin at the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial. In total, 306 patients were enrolled and received at least one dose of randomised treatment (204 isepamicin, 102 amikacin: intent-to-treat population); 181 patients satisfied all criteria for evaluability (120 isepamicin, 61 amikacin: efficacy population). Clinical cure or improvement rates in the isepamicin and amikacin groups were: intent-to-treat population, 188/204 (92%) and 94/102 (92%), respectively; efficacy population, 117/120 (98%) and 58/61 (95%), respectively. The bacteriological elimination rate (efficacy population) in the isepamicin and amikacin treatment groups was 75/76 (99%) vs 35/38 (92%). Nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or ≥44.2 μmol/L from baseline, occurred in 4/187 (2%) and 1/91 (1%) children treated with isepamicin and amikacin, respectively. Definite ototoxicity at the ≥20 dB threshold occurred in 3 (1 isepamicin and 2 amikacin) out of 56 children evaluated with at least two audiograms. Thus isepamicin was as effective and as well tolerated as amikacin in the treatment of various infections in paediatric patients.

KW - Amikacin

KW - Aminoglycoside

KW - Isepamicin

KW - Paediatrics

UR - http://www.scopus.com/inward/record.url?scp=0028864051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028864051&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 95

EP - 101

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 2

ER -